{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T01:25:06Z","timestamp":1776389106459,"version":"3.51.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Ulcerative colitis (UC) is a chronic and progressive inflammatory disease of the intestines, marked by recurrent inflammation along the digestive tract, leading to symptoms such as bloody diarrhea and weight loss, severely impacting patients\u2019 quality of life. Despite extensive research, current therapeutic treatment for UC still faces challenges in long-term efficacy and safety. Lanatoside C (LanC), as a type of cardiac glycosides, has shown promising anti-inflammatory effects. This study employs network pharmacology to investigate the effects and mechanisms of LanC in the treatment of UC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>LanC- and UC-associated target genes datasets were retrieved from the Genecards, DisGeNET, and Gene Expression Omnibus database. Integration analysis identified a common set of potential LanC targets for UC treatment. Analyses of Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed on these target genes. Additionally, a protein-protein interaction (PPI) network was constructed to identify the top targets with the highest connectivity. Molecular docking and cellular experiments were subsequently carried out to further validated these findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>23 intersecting genes were identified as potential targets of LanC in UC. Among these, KDR, STAT3, ABCB1, CYP3A5, and CYP2B6 emerged as the top 5 targets with high therapeutic potential. Pathway analysis indicated the involvement of fatty acid and lipid metabolism, as well as xenobiotic metabolism pathways, which could be crucial for LanC\u2032s efficacy in treating UC. Molecular docking simulations revealed favorable binding interaction between LanC and KDR, STAT3, ABCB1, CYP3A5, and CYP2B6. Furthermore, <jats:italic>In vitro<\/jats:italic> experiments demonstrated that LanC significantly inhibits LPS-induced pro-inflammatory cytokines expression in RAW264.7 cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrates a comprehensive overview of the therapeutic potential of LanC in UC and elucidates its mechanisms of action. These findings offer a theoretical basis for further optimizing UC clinical therapy and underscore the potential of LanC as a novel therapeutic option for UC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmolb.2025.1552360","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T13:48:34Z","timestamp":1742564914000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Network pharmacology analysis of Lanatoside C: molecular targets and mechanisms in the treatment of ulcerative colitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Wenjing","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"970890","DOI":"10.1155\/2015\/970890","article-title":"Angiogenesis in inflammatory bowel disease","volume":"2015","author":"Alkim","year":"2015","journal-title":"Int. J. Inflam."},{"key":"B2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.dld.2021.03.002","article-title":"Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review","volume":"53","author":"Armuzzi","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"17562848221138160","DOI":"10.1177\/17562848221138160","article-title":"A review of the therapeutic management of ulcerative colitis","volume":"15","author":"Aslam","year":"2022","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1021\/acscombsci.0c00082","article-title":"Prospects and therapeutic applications of cardiac glycosides in cancer remediation","volume":"22","author":"Ayogu","year":"2020","journal-title":"ACS Comb. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/toxins13050344","article-title":"Quo vadis cardiac glycoside research?","volume":"13","author":"Bejcek","year":"2021","journal-title":"Toxins (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.toxicon.2018.11.429","article-title":"A review of cardiac glycosides: structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential","volume":"158","author":"Botelho","year":"2019","journal-title":"Toxicon"},{"key":"B7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12943-024-02108-6","article-title":"Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer","volume":"23","author":"Chen","year":"2024","journal-title":"Mol. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12935-019-0806-1","article-title":"New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin","volume":"19","author":"Cheng","year":"2019","journal-title":"Cancer Cell Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"158017","DOI":"10.1016\/j.scitotenv.2022.158017","article-title":"Gene\/environment interaction in the susceptibility of Crohn's disease patients to aluminum","volume":"850","author":"Djouina","year":"2022","journal-title":"Sci. Total Environ."},{"key":"B10","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis. Mon."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1097\/MIB.0000000000000180","article-title":"Stat3: friend or foe in colitis and colitis-associated cancer?","volume":"20","author":"Han","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.05.001","article-title":"STAT3 signaling in immunity","volume":"31","author":"Hillmer","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.freeradbiomed.2022.06.242","article-title":"STAT3-mediated ferroptosis is involved in ulcerative colitis","volume":"188","author":"Huang","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s42003-021-01787-x","article-title":"Cardiac glycosides target barrier inflammation of the vasculature, meninges and choroid plexus","volume":"4","author":"Jansson","year":"2021","journal-title":"Commun. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jss.2013.04.026","article-title":"Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis","volume":"184","author":"Knod","year":"2013","journal-title":"J. Surg. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/biom11091275","article-title":"Emergence of cardiac glycosides as potential drugs: current and future scope for cancer therapeutics","volume":"11","author":"Kumavath","year":"2021","journal-title":"Biomolecules"},{"key":"B19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/sj.tpj.6500413","article-title":"ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research","volume":"7","author":"Leschziner","year":"2007","journal-title":"Pharmacogenomics J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2400206","DOI":"10.1002\/advs.202400206","article-title":"Gingerenone A attenuates ulcerative colitis via targeting IL-17ra to inhibit inflammation and restore intestinal barrier function","volume":"11","author":"Liang","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","article-title":"Current and emerging therapeutic targets for IBD","volume":"14","author":"Neurath","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1440-1681.13081","article-title":"Lanatoside C protects mice against bleomycin-induced pulmonary fibrosis through suppression of fibroblast proliferation and differentiation","volume":"46","author":"Nie","year":"2019","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/bph.15423","article-title":"Cardiac glycosides cause cytotoxicity in human macrophages and ameliorate white adipose tissue homeostasis","volume":"179","author":"Olona","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"113990","DOI":"10.1016\/j.phytochem.2024.113990","article-title":"Cardiac glycosides from Streblus asper with potential antiviral activity","volume":"219","author":"Ouyang","year":"2024","journal-title":"Phytochemistry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.3390\/molecules25163596","article-title":"Anticancer and antiviral properties of cardiac glycosides: a review to explore the mechanism of actions","volume":"25","author":"Reddy","year":"2020","journal-title":"Molecules"},{"key":"B26","doi-asserted-by":"publisher","first-page":"G153","DOI":"10.1152\/ajpgi.00395.2004","article-title":"Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-\/- mice","volume":"289","author":"Resta-Lenert","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/biom11050659","article-title":"Cardiac glycosides as immune system modulators","volume":"11","author":"Skubnik","year":"2021","journal-title":"Biomolecules"},{"key":"B28","doi-asserted-by":"publisher","first-page":"156048","DOI":"10.1016\/j.phymed.2024.156048","article-title":"Puerarin ameliorates colitis by direct suppression of macrophage M1 polarization in DSS mice","volume":"135","author":"Tao","year":"2024","journal-title":"Phytomedicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"599281","DOI":"10.3389\/fcell.2020.599281","article-title":"Molecular bases of VEGFR-2-mediated physiological function and pathological role","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1021\/acs.molpharmaceut.9b00459","article-title":"Crohn's disease is associated with decreased CYP3A4 and P-glycoprotein protein expression","volume":"16","author":"Wilson","year":"2019","journal-title":"Mol. Pharm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/molecules28010068","article-title":"Investigating the mechanisms of bisdemethoxycurcumin in ulcerative colitis: network pharmacology and experimental verification","volume":"28","author":"Wu","year":"2022","journal-title":"Molecules"},{"key":"B32","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13046-024-03132-6","article-title":"tsRNA-GlyGCC promotes colorectal cancer progression and 5-FU resistance by regulating SPIB","volume":"43","author":"Xu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.3748\/wjg.v19.i17.2638","article-title":"Expression of interleukin-22\/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis","volume":"19","author":"Yu","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/molecules28010146","article-title":"Efficacy and mechanism of quercetin in the treatment of experimental colitis using network pharmacology analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Molecules"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1552360\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T13:48:39Z","timestamp":1742564919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1552360\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":34,"alternative-id":["10.3389\/fmolb.2025.1552360"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2025.1552360","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"1552360"}}